In COVID-19, gene variants in the complement pathway, specifically CD59, CFH and C4BPa are associated with poorer outcomes (15) and targeted studies have demonstrated elevations of C5a and C5b-9 in plasma from individuals with moderate and severe disease (16). The gene discussed is CFH; the disease is COVID-19.